Insider buying last 90 days
No open-market insider purchases were filed for BVS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BVS insider filing, plotted on the chart in Gekko.Open BVS in Gekko
NASDAQ: BVS
Bioventus (BVS) Stock Analysis & Forecast
Oct 12 close
$13.53+0.46 (+3.5%)
Gekko Brief
Oct 12 closeBioventus closed at $13.53 on 12 October 2026, +3.5% on the day. The price sits between the 50-day ($13.69) and 200-day ($10.44) moving averages, inside a 52-week range of $6.37 to $15.89. The GekkoIndex reads 59, in the Neutral zone, down 0.9 points over five sessions. Gekko Fair Value is $15.25, so the price is 11.3% below it.
The next earnings report is due on 3 November 2026, 22 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 8.7% across the report. Seasonally, the next 20 trading days from this point averaged +7.9% over the last 5 years, rising in 4 of them.
4 firms rate the stock: 4 buy, 0 hold and 0 sell, with a consensus target of $17.60. A typical daily move is about 3.4%, and a typical 20-day move about 11.7%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Bioventus price vs fair value
Close $13.53200-day averageGekko Fair Value $15.25
Bioventus quick facts
- Market cap
- $916.6M
- P/E ratio
- 16.4
- Forward P/E
- 14.8
- EPS, TTM
- $0.78
- Revenue, TTM
- $581.8M
- Profit margin
- 9.4%
- Dividend yield
- —
- Beta
- 0.64
- Volume
- 444,560 avg 436,555
- 1-year return
- +105.3%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±11.7%
- 50-day average
- $13.69
- 200-day average
- $10.44
- Next earnings
- Nov 3 before open
- Shares outstanding
- 68.31M
Bioventus swing-trade checklist
Bioventus scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $13.53 sits between the 50-day ($13.69) and 200-day ($10.44) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59, Neutral
Reading 59 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
11.3% below
Price is 11.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.9% on average
From this point in the calendar, the next 20 trading days averaged +7.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bioventus stock chart and price history
Bioventus closed at $13.53 on Oct 12, 2026, +105.3% over the past year, inside a 52-week range of $6.37 to $15.89.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.2%
- 3 months
- +17.0%
- 6 months
- +43.6%
- 1 year
- +105.3%
The full BVS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BVS in Gekko
Follow Bioventus through every session
Put BVS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BVS in GekkoFree for 7 days. No credit card required.
About Bioventus
Bioventus makes medical devices aimed at easing pain and treating musculoskeletal conditions, serving patients in the United States and other countries. Its offerings span injections for joint pain, including hyaluronic acid treatments for knee osteoarthritis, along with nerve stimulation devices for chronic pain and tools used in spine and bone surgery. The company also supplies bone graft materials, ultrasonic surgical systems for cutting and cleaning tissue, and a system for producing concentrated platelet-rich plasma from blood samples.
Beyond surgical and injectable products, Bioventus provides devices for fracture healing and rehabilitation, such as an ultrasound-based bone stimulation system. Its customer base includes hospitals and other healthcare institutions, individual physicians, patients, and a network of distributors and dealers who help bring these products to market.
The company was established in 2011 and operates out of Durham, North Carolina. Its shares trade on the NASDAQ under the ticker BVS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- bioventus.com
Bioventus GekkoIndex: the smart money zone
Bioventus’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59, in the Neutral zone, down 0.9 points over five sessions.
59Neutral
Down 0.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 31 | +4.5% | +15.7% | ||
| Accumulation | 210 | +0.7% | +6.3% | ||
| Neutral (current zone) | 406 | +0.9% | +2.5% | ||
| Distribution | 34 | +1.4% | +6.7% | ||
| Selling | 1 | Too few readings yet | |||
Average BVS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BVS price, zone by zone.Track BVS in Gekko
Is Bioventus stock overvalued? Gekko Fair Value
Bioventus trades 11.3% below Gekko Fair Value of $15.25, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Bioventus shares are worth, recalculated every trading day.
$15.25
Gekko Fair Value, Oct 9, 2026
11.3% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BVS in Gekko
Bioventus insider and Congress trading
No open-market insider purchases were filed for Bioventus, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BVS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BVS, plotted on the chart in Gekko.Open BVS in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BVS.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Bioventus earnings: next date and track record
Bioventus reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- $0.15
- Revenue estimate
- $149.5M
6 of 8reports beat the EPS estimate
±8.7%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Bioventus reported Q2 2026 revenue growth of 4%, led by strong double-digit growth in the Pain Treatments segment, particularly the HA franchise driven by DUROLANE. The company disclosed a strategic review following unsolicited acquisition interest, with a board committee evaluating options including a potential sale. Management is investing in growth drivers including PRP, PNS, Ultrasonics, and International markets while maintaining earnings improvement.
- Guidance
- Bioventus reiterated full year 2026 guidance on all metrics, expressing confidence in long-range growth prospects. Management highlighted accelerating capital placements in PRP and continued commercial expansion as positive leading indicators for future performance.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.22 est $0.22 | $153.2M est $155.4M | +4.2% |
| May 6, 2026 | $0.15 est $0.09 | $132.1M est $129.9M | −0.3% |
| Mar 5, 2026 | $0.24 est $0.22 | $157.9M est $154.9M | −0.7% |
| Nov 4, 2025 | $0.15 est $0.22 | $138.7M est $155.7M | +12.5% |
| Aug 6, 2025 | $0.21 est $0.22 | $147.7M est $138.8M | +12.9% |
| May 6, 2025 | $0.08 est $0.06 | $123.9M est $145.9M | −6.3% |
| Mar 11, 2025 | $0.15 est $0.08 | $153.6M est $124.5M | +15.0% |
| Nov 5, 2024 | $0.06 est $0.03 | $139.0M est $144.8M | −17.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bioventus stock forecast and analyst price targets
Analysts’ average 12-month price target for Bioventus is $17.60, +30.1% from the last close, from 4 firms rating the stock in the last 90 days.
$17.60consensus 12-month target, +30.1% from the last close
Now $13.53Avg $17.60
Low $15High $19
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 17 | Cantor Fitzgerald | $15 | +10.9% |
| Aug 17 | Canaccord Genuity | $19 | +40.4% |
| Aug 6 | Craig-Hallum | $18 | +33.0% |
| Aug 6 | Barrington | $18 | +33.0% |
| Aug 5 | Canaccord Genuity | $15 | +10.9% |
+2.5%average 20-day move after past Neutral readings
+7.9%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bioventus seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Bioventus averaged +7.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.2% | 3 of 5 |
| Next 10 trading days | +4.7% | 3 of 5 |
| Next 15 trading days | +12.0% | 5 of 5 |
| Next 20 trading days | +7.9% | 4 of 5 |
| Next 30 trading days | −11.3% | 2 of 5 |
For scale, BVS’s typical 20-trading-day move in either direction is about 11.7%.
Bioventus market cap and key statistics
Bioventus’s market cap is $916.6M, with a P/E ratio of 16.4 and revenue of $581.8M over the last twelve months.
Valuation
- Market cap
- $916.6M
- P/E ratio
- 16.4
- Forward P/E
- 14.8
- EPS, TTM
- $0.78
- Gekko Fair Value
- $15.25
Trading
- Volume
- 444,560
- Avg volume, 20 days
- 436,555
- 52-week high
- $15.89
- 52-week low
- $6.37
- Shares outstanding
- 68.31M
Financials
- Revenue, TTM
- $581.8M
- Profit margin
- 9.4%
- Return on equity
- 25.7%
- Quarterly earnings growth, YoY
- +327.3%
Risk and income
- Beta
- 0.64
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±11.7%
Bioventus stock news this week
2 headlines about Bioventus from the past week, newest first, each linking to the publisher.
- Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)Defense World, Oct 12
- Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)Defense World, Oct 6
Bioventus peers
Bioventus’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Bioventus stock FAQ
What is Bioventus’s market cap?
Bioventus’s market cap is $916.6M at the Oct 12, 2026 close of $13.53, with 68.31M shares outstanding. The shares trade on a P/E ratio of 16.4.
What is the Bioventus stock forecast?
The consensus analyst 12-month price target for Bioventus is $17.60, +30.1% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Bioventus stock overvalued or undervalued?
On Gekko’s estimate Bioventus is undervalued: the Oct 12, 2026 close of $13.53 is 11.3% below Gekko Fair Value of $15.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bioventus report earnings next?
Bioventus is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of $0.15 per share on revenue of $149.5M. Bioventus beat the earnings estimate in 6 of its last 8 reports, moving 8.7% on average across the report.
What is Bioventus’s 52-week high and low?
Bioventus’s 52-week high is $15.89 and its 52-week low is $6.37; it closed at $13.53 on Oct 12, 2026, +105.3% over the past year. Over the last five years the shares peaked at $17.53 on Nov 10, 2021.
Is Bioventus stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bioventus the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.